Reduction in the frequency of Bacillus Calmette-Guérin (BCG) vaccine instillations during induction and maintenance treatment for non-muscle-invasive bladder cancer (NMIBC) results in earlier disease recurrence relative to a standard instillation schedule.
Prof. Marc-Oliver Grimm (University Hospital Jena, Germany) presented an analysis of the recurrence risk in patients with high grade NMIBC in the randomised phase 3 NIMBUS trial . Prof. Grimm explained that, given the BCG shortage and the known BCG-associated toxicities, NIMBUS set out to investigate whether a reduced frequency of BCG instillations during induction and maintenance would result in noninferior clinical efficacy, with potentially fewer adverse events, as well as reduced inconvenience and cost. The primary endpoint was time to first recurrence. Key secondary outcomes were the number and grade of recurrent tumours, the rate of progression to muscle-invasive disease, and safety.
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Prostatectomy: R-LRPE better than LRPE for continence Next Article
Adofaragene firadenovec effective in BCG-unresponsive papillary NMIBC: phase 3 results »
Table of Contents: EAU 2020
Surgical Techniques and Safety
Prostate Cancer & Imaging
BPH & LUTS
Testis Cancer & Andrology
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.